Introduction
============

Type 2 diabetes mellitus is characterized by abnormalities in carbohydrate, fat, and protein metabolism due to insulin resistance \[[@B1]\]. Cardiovascular complications are a major cause of premature mortality in patients with type 2 diabetes \[[@B2]\], and tight control of hyperglycemia and dyslipidemia is crucial for reducing the risk for cardiovascular diabetic complications \[[@B3],[@B4]\].

α-Glucosidase inhibitors are oral hypoglycemic agents for patients with type 2 diabetes that inhibit digestion of dietary carbohydrates and thereby flatten the postprandial glucose response. Although α-glucosidase inhibitors such as acarbose and miglitol effectively alleviate both fasting and postprandial hyperglycemia \[[@B5],[@B6]\], chronic use of these agents can result in gastrointestinal side effects \[[@B7]\]. As a result, many efforts have been made to isolate α-glucosidase inhibitors from natural products with reduced side effects, including plants. Plant leaves such as green tea \[[@B8]\], olive leaf \[[@B9]\], and guava leaf \[[@B10]\] have reported to show potent inhibitory activity against α-glucosidase activity.

Lotus (*Nelumbo nuficera* Gaertn), an aquatic perennial plant that belongs to the family *Nelumbonaceae*, is cultivated as a crop mainly in eastern Asia and India \[[@B11]\]. Its seeds, young stems, and rhizomes are consumed as food, whereas the leaves are mainly used for tea. Different parts of the lotus plant have also been used to treat diarrhea, tissue inflammation, and hemostasis in traditional medicine \[[@B12]\].

Lotus leaves could be helpful in the management of diabetes mellitus, as a lotus leaf extract has α-glucosidase inhibitory activity *in vitro* \[[@B8]\]. Therefore, lotus leaf is expected to be effective for preventing the rise in postprandial glucose levels, but the α-glucosidase inhibitory activity of lotus leaf had not been fully determined *in vivo*. Chronic consumption of lotus leaf reduces fasting blood glucose and improves blood lipid profiles in alloxan-treated mice, suggesting that it could be beneficial for managing type 1 diabetes mellitus \[[@B13]\]. However, the hypoglycemic and hypolipidemic effects of lotus leaf in type 2 diabetes remain unclear. This study was carried out to examine the acute effects of lotus leaf on postprandial hyperglycemia in streptozotocin (STZ)-induced diabetic rats. We also investigated the effect of chronic consumption of lotus leaf on fasting hyperglycemia and dyslipidemia in db/db mice, an animal model of type 2 diabetes that shows insulin resistance, hyperglycemia, and dyslipidemia.

Materials and Methods
=====================

Reagents
--------

Assay kits for glucose, triglycerides (TG), total cholesterol (CHOL), and high-density lipoprotein (HDL)-CHOL were obtained from Asan Co. (Seoul, Korea). An insulin assay kit and a glycated hemoglobin (HbA~1C~) assay kit were purchased from Linco Co. (St. Charles, MO, USA) and BioSystems (Barcelona, Spain). Yeast α-glucosidase, *p*-nitropheny-α-D-glucopyranoside, STZ, and all other chemical reagents were obtained from Sigma Chemical Co. (St. Louis, MO, USA).

Preparation of the lotus leaf extract
-------------------------------------

Lotus leaves were obtained from a local market in Muan, Korea. The leaves were freeze-dried, powdered, and extracted with 10 volumes of ethanol for 12 h twice at room temperature, and the solvent was removed by rotary evaporation \[[@B14]\]. The extraction yield was 12.3%. The dry extract was redissolved in dimethyl sulfoxide at a concentration of 5 mg/mL to be used as a test material for the *in vitro* study. The solvent was removed by rotary evaporation.

Enzyme inhibition assay
-----------------------

Yeast α-glucosidase inhibitory activity was measured using a microplate reader (model 550; Bio-Rad, Hercules, CA, USA) according to the method described by Watanabe et al. \[[@B15]\]. Yeast α-glucosidase (0.7 U) dissolved in 100 mM phosphate buffer (pH 7.0) containing 2 g/L bovine serum albumin and 0.2 g/L NaN~3~ and 5 mM *p*-nitrophenyl-α-D-glucopyranoside in the same buffer (pH 7.0) was used as enzyme and substrate solutions, respectively. The final concentration of the lotus leaf extract and acarbose, a positive control, was 0.5 mg/mL. Measurements were performed in triplicate.

Measurement of postprandial blood glucose response in diabetic rats
-------------------------------------------------------------------

Male Sprague-Dawley rats (weight 220-250 g; Bio Genomics, Inc., Seoul, Korea) were fed a commercial chow (Samyang Co., Seoul, Korea) *ad libitum* for 2 weeks after arrival. The animals were maintained under standard laboratory conditions of 24 ± 5℃ and 55 ± 5% relative humidity with a 12-h light:12-h dark cycle. STZ (60 mg/kg) in citrate buffer (pH 4.5) was injected intraperitoneally into the animals to induce diabetes \[[@B16]\]. Blood samples were withdrawn from the tail tip after 1 week, and blood glucose concentrations were measured using a glucometer (Glucotrend; Roche Diagnostics, West Sussex, UK). Animals with fasting blood glucose levels \> 200 mg/dL (n = 16) were considered diabetic and randomly divided into three groups. After an overnight fast, the animals were administered soluble starch (1 g/kg) alone (control group), or starch with an ethanol extract of lotus leaf (500 mg/kg) by gastric intubation \[[@B14]\]. Feed was withheld during the test. Blood samples were collected from the tail vein after 30, 60, 120, 180, and 240 min and centrifuged at 1,000 g for 15 min. Plasma glucose was measured by enzymatic method using a commercial glucose assay kit \[[@B17]\]. Plasma glucose levels are expressed as increases from the baseline, and increases in the areas under the response curves (AUC) were calculated using the trapezoidal rule.

Measurement of hypoglycemic effect following chronic consumption of lotus leaf by db/db mice
--------------------------------------------------------------------------------------------

Five-week-old male C57BL/KsJ-db/db mice (n = 16) were purchased from SLC Japan (Shizuoka, Japan). The animals had free access to commercial food during a 1-week acclimation period and were then randomly divided into a control and the lotus-leaf groups. The mice in the control group were offered an AIN-93G diet composed of 39.8% cornstarch, 20% casein, 13.2% dextrinized cornstarch, 10% sucrose, 7% soybean oil, 5% Alphacel, 3.5% mineral mixture, 1% vitamin mixture, 0.3% L-cysteine, 0.25% choline bitartrate, and 0.0014% *tert*-butyl hydroquinone \[[@B18]\], whereas the lotus leaf group was fed the same diet supplemented with 1% (w/w, final concentration) lotus leaf extract in place of cornstarch *ad libitum* for 7 weeks. After an overnight fast, the mice were sacrificed by heart puncture. Plasma glucose \[[@B17]\], TG \[[@B19]\], total CHOL \[[@B20]\], and HDL-CHOL levels \[[@B21]\] were measured by enzymatic methods using commercial assay kits. Blood HbA~1C~ \[[@B22]\] and plasma insulin levels \[[@B23]\] were measured using a chromatographic assay and radioimmunoassay kits, respectively. The homeostasis model assessment for insulin resistance (HOMA-IR) was calculated by dividing the product of insulin (µU/mL) and glucose (mmol/L) by 22.5 \[[@B24]\].

All animal experiments were performed according to the guidelines of animal experimentation approved by the Animal Resource Center at Inje University, Korea.

Statistical analysis
--------------------

All data are expressed as the mean ± standard error (SE). Differences between the control and the lotus leaf groups were assessed using Student\'s *t*-test (*P* \< 0.05).

Results
=======

Inhibition of α-glucosidase activity *in vitro* and alleviation of postprandial hyperglycemia by the lotus leaf extract
-----------------------------------------------------------------------------------------------------------------------

The *in vitro* inhibitory activity of the lotus leaf ethanol extract against yeast α-glucosidase is shown in [Table 1](#T1){ref-type="table"}. The lotus leaf extract inhibited yeast α-glucosidase activity by 37.9% at a concentration of 0.5 mg/mL, whereas acarbose showed a 29.6% inhibition.

The effect of lotus leaf on the postprandial rise in blood glucose in STZ-induced diabetic rats was determined by carbohydrate load testing. Oral administration of lotus leaf extract (500 mg/kg) significantly decreased the increase in plasma glucose levels at 30 (*P* \< 0.05), 60 (*P* \< 0.01), and 120 min (*P* \< 0.05) after starch loading (1 g/kg) ([Fig. 1](#F1){ref-type="fig"}). Consumption of the lotus leaf extract in the rats decreased the AUCs for the postprandial glucose responses by 35.1%, compared with those in the control group (*P* \< 0.01; [Table 2](#T2){ref-type="table"}).

Effect of chronic consumption of lotus leaf extract on fasting hyperglycemia and dyslipidemia in db/db mice
-----------------------------------------------------------------------------------------------------------

Body weight, food intake, and feed efficiency ratio of db/db mice were not significantly influenced by consuming the lotus leaf extract (1% of diet; [Table 3](#T3){ref-type="table"}). Plasma glucose levels were significantly lower in the lotus leaf group (427.6 ± 18.3 mg/dL) than in the control group (496.0 ± 21.3 mg/dL; *P* \< 0.05; [Fig. 2](#F2){ref-type="fig"}). Plasma insulin levels of the lotus leaf group (63.8 ± 2.8 µU/mL) were not significantly different from that of the control group (65.3 ± 2.5 µU/mL), whereas consuming the lotus leaf extract significantly reduced the HOMA-IR value by 15.6% compared with that in the control group (*P* \< 0.01). HbA~1C~ levels in the lotus leaf group (7.5 ± 0.3%) were lower than those in the control group (8.4 ± 0.3%; *P* \< 0.05).

Consumption of the lotus leaf extract significantly lowered plasma TG (135.4 ± 5.5 mg/dL) and total CHOL levels (155.5 ± 7.0 mg/dL) compared with those in the control group (152.0 ± 5.7 and 180.0 ± 8.2 mg/dL, respectively; *P* \< 0.05). Plasma HDL-CHOL levels were significantly elevated in the lotus leaf group (70.2 ± 3.6 mg/dL) compared with those in the control group (58.8 ± 2.9 mg/dL; *P* \< 0.01; [Fig. 3](#F3){ref-type="fig"}).

Discussion
==========

We determined the α-glucosidase inhibitory activity of a lotus leaf extract *in vitro* and *in vivo* to evaluate the potential of the lotus leaf extract as a hypoglycemic agent for diabetes mellitus. Yeast α-glucosidase inhibitory activity of the lotus leaf extract was 1.3 times stronger than that of acarbose at a concentration of 0.5 mg/mL *in vitro* ([Table 1](#T1){ref-type="table"}). Lin et al. \[[@B25]\] isolated catechin and quercetin from lotus leaf as its active constituents; catechin \[[@B26]\] and quercetin \[[@B27],[@B28]\] have strong inhibitory activity against α-glucosidase *in vitro* and *in vivo*. Therefore, the α-glucosidase inhibitory activity of lotus leaf could be due to catechin and quercetin content.

The inhibitory activity of the lotus leaf extract against α-glucosidase was further determined in STZ-induced diabetic rats to verify its effect *in vivo*. A single oral dose of lotus leaf extract (500 mg/kg) was effective in flattening the postprandial rise in plasma glucose levels ([Fig. 1](#F1){ref-type="fig"}) and reducing the AUC of the glucose response curve in the animals ([Table 2](#T2){ref-type="table"}). Control of both fasting and postprandial hyperglycemia is crucial for maintaining tight control of blood glucose levels in patients with diabetes \[[@B29]\]. Increasing evidence from epidemiological and interventional studies suggests that postprandial hyperglycemia might be a more important marker of risk for cardiovascular diabetic complications than fasting hyperglycemia \[[@B30]\]. Thus, alleviating postprandial hyperglycemia by administering lotus leaf extract could be helpful in the management of diabetes.

The hypoglycemic and hypolipidemic effect of chronic consumption of lotus leaf was determined in db/db mice. Lotus leaf extract consumed at 1% of the total diet decreased fasting plasma glucose and blood HbA~1c~ by 13.8% and 10.5%, respectively, without influencing insulin levels in db/db mice ([Fig. 2](#F2){ref-type="fig"}). The lotus leaf extract reduced the HOMA-IR index, suggesting improved insulin resistance. Impaired postprandial glucose elevations by acarbose, an α-glucosidase inhibitor, has been demonstrated to alleviate glucose toxicity, resulting in overall blood glucose control \[[@B31]\]. In addition, consuming a lotus leaf extract for 2 weeks improved insulin sensitivity in high-fat diet-fed mice determined by the insulin tolerance test \[[@B32]\]. Lotus leaf extract may be able to improve fasting hyperglycemia by reducing glucose toxicity and increasing insulin sensitivity. HbA~1c~ is considered to be the best marker for long-term blood glycemic control \[[@B33]\] and is strongly associated with the incidence of diabetic complications \[[@B34],[@B35]\]. Thus, reduced blood glucose and HbA~1c~ in response to lotus leaf treatment could contribute to a lower risk of diabetic complications.

Insulin resistance has been reported to contribute to development of dyslipidemia \[[@B36]-[@B38]\]. Insulin resistance elevates free fatty acid flux, increasing hepatic production of TG and very-low-density lipoprotein (VLDL), which is converted to TG-rich remnants \[[@B36]\]. VLDL remnants interfere with the clearance of chylomicron remnants, causing hypertriglyceridemia \[[@B37]\]. Increased exchange between the cholesteryl esters of HDL and TG of TG-rich lipoproteins lowers blood HDL-CHOL \[[@B38]\]. Thus, insulin resistance could induce hypertriglyceridemia and reduction in HDL-CHOL in db/db mice. However, the results of this study showed that the lotus leaf extract effectively alleviated hypertriglyceridemia and hypercholesterolemia and elevated HDL-CHOL levels in db/db mice ([Fig. 3](#F3){ref-type="fig"}). Therefore, improved insulin sensitivity due to administration of a lotus leaf extract could contribute to controlling dyslipidemia, which is important in reducing the risk of micro and macrovascular complications in patients with diabetes \[[@B39]\].

Hypolipidemic effect of lotus leaf could have been partly mediated by catechin and quercetin in this study. Catechin ameliorates plasma lipid profiles by reducing lipogenic gene expression such as sterol regulatory element-binding protein-1c (SREBP-1c) and fatty acid synthase (FAS) and inducing lipolytic gene expression such as hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL) in high-fat diet-induced obese mice \[[@B40]\]. Quercetin decreases TG synthesis by reducing SREBP-1c expression in the liver of mice fed a western diet \[[@B41]\]. The lotus leaf extract could modulate gene expression of SREBP-1c, FAS, HSL, or ATGL. Further study is necessary to identify the active components that mediate the hypoglycemic and hypolipidemic effects of lotus leaf and to understand the underlying mechanisms of action.

In conclusion, lotus leaf was effective in controlling postprandial hyperglycemia in STZ-induced diabetic rats and fasting hyperglycemia in db/db mice. Lotus leaf also alleviated hypertriglyceridemia and hypercholesterolemia and increased HDL-CHOL in db/db mice. These results suggest that lotus leaf could play a beneficial role in management of hyperglycemia and dyslipidemia in animal model of diabetes mellitus.
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![**Increase in blood glucose after administration of lotus leaf extract in STZ-induced diabetic rats.** Control group (●): Starch (1 g/kg) was administered orally to streptozotocin-induced diabetic rats after an overnight fast. Lotus leaf group (■): Starch (1 g/kg) plus ethanol extract of lotus leaf (500 mg/kg) was administered orally to the rats after an overnight fast. Values represent means ± SE (n = 8). ^\*^Significantly different at *P* \< 0.05, ^\*\*^Significantly different at *P* \< 0.01, ns; not significant.](nrp-7-166-g001){#F1}

![**Hypoglycemic effects of lotus leaf extract in db/db mice.** (A) Blood glycated hemoglobin (HbA~1C~), (B) Plasma glucose, (C) Plasma insulin and (D) HOMA-IR. The control group was fed a standard AIN-93G diet, whereas the treatment group was fed a diet containing 1% ethanol extract of lotus leaf *ad libitum* for 7 weeks. Values represent means ± SE (n = 8). ^\*^Significantly different at *P* \< 0.05, ns; not significant.](nrp-7-166-g002){#F2}

![**Hypolipidemic effects of lotus leaf extract in db/db mice.** (A) Plasma triglycerides, (B) Plasma total cholesterol and (C) Plasma HDL-cholesterol. The control group was fed a standard AIN-93G diet, whereas the treatment group was fed a diet containing 1% ethanol extract of lotus leaf *ad libitum* for 7 weeks. Values represent means ± SE (n = 8). ^\*^Significantly different at *P* \< 0.05, ^\*\*^Significantly different at *P* \< 0.01.](nrp-7-166-g003){#F3}

###### 

Inhibitory activities of lotus leaf against yeast α-glucosidase

![](nrp-7-166-i001)

The inhibitory activities of the ethanol extracts of lotus leaf and acarbose were measured at a concentration of 0.5 mg/mL. Values represent means ± SE of triplicate measurements.

###### 

Area under the glucose response curve of STZ-induced diabetic rats

![](nrp-7-166-i002)

Control group: Starch (1 g/kg) was administered orally to streptozotocin-induced diabetic rats after an overnight fast. Lotus leaf group: Starch (1 g/kg) plus ethanol extract of the lotus leaf (500 mg/kg) was administered orally to the rats after an overnight fast. Values represent means ± SE (n = 8). ^\*\*^Significantly different at *P* \< 0.01.

###### 

Body weight, food intake, and feed efficiency ratio in db/db mice fed control and lotus leaf diet

![](nrp-7-166-i003)

The control group was fed a standard AIN-93G diet, whereas the treatment group was fed a diet containing 1% ethanol extract of lotus leaf *ad libitum* for 7 weeks.

Values represent mean ± SE.

^1)^Feed efficiency ratio (%) = (Body weight gain \[g\]/food intake \[g\]) × 100

^2)^Not significant
